Loading...
OptimizeRx reported a solid start to 2023 with total revenue of $13.0 million. The company's execution remains on pace to meet its 2023 financial and operational objectives.
Total revenue was $13.0 million.
GAAP net loss per share was $(0.37).
Non-GAAP net loss per share was $(0.09).
Reaffirmed full year financial outlook for net revenue to increase at least 10% year-over-year.
The Company is reaffirming its full year financial outlook for fiscal 2023 for net revenue to increase at least 10% year-over-year, and gross margins to be between 58% and 62%.